US 12,257,230 B2
Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment
Hong Seob So, Iksan-si (KR); Hyung-Jin Kim, Iksan-si (KR); Gi-Su Oh, Iksan-si (KR); Seunghoon Lee, Iksan-si (KR); and Dipendra Khadka, Iksan-si (KR)
Assigned to NADIANBIO Ltd., Iksan-si (KR)
Appl. No. 16/097,028
Filed by NADIANBIO LTD., Iksan-si (KR)
PCT Filed Apr. 28, 2017, PCT No. PCT/KR2017/004600
§ 371(c)(1), (2) Date Oct. 26, 2018,
PCT Pub. No. WO2017/188791, PCT Pub. Date Nov. 2, 2017.
Claims priority of application No. 10-2016-0053171 (KR), filed on Apr. 29, 2016.
Prior Publication US 2019/0083453 A1, Mar. 21, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 31/337 (2006.01); A61K 31/343 (2006.01); A61K 31/65 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01); A61P 3/00 (2006.01); A61P 7/00 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 31/337 (2013.01); A61K 31/343 (2013.01); A61K 31/65 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); A61P 3/00 (2018.01); A61P 7/00 (2018.01); A61P 21/00 (2018.01); A61P 25/00 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01)] 5 Claims
OG exemplary drawing
 
1. A method for ameliorating cancer-related fatigue and/or cachexia of a subject,
said method comprising administering an effective amount of the compound of Formula 1 below or a pharmaceutically acceptable salt thereof to the subject,
wherein the subject suffers from cancer and receives a chemo-therapy using an anticancer drug,
wherein the anticancer drug is a combination of adriamycin, cyclophosphamide, and paclitaxel (ACP);
wherein the compound of formula 1 or the pharmaceutically acceptable salt thereof reduces expression of inflammatory cytokines in hypothalamus, blood, and bone marrow;
wherein the inflammatory cytokines are one or more cytokines selected from the group consisting of TNF-α, IL-1ß, IL-6, and IL-17;

OG Complex Work Unit Chemistry
 and
wherein the effective amount of the compound of formula 1 or the pharmaceutically acceptable salt thereof is 20 mg/kg to 80 mg/kg.